Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J. Jaehnig, Meenakshi Anurag, Aranzazu Fernandez-Martinez et al.|Cell Reports Medicine|2025Cited by 3
Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Xuxu Gou et al.|Unknown|2023Cited by 0
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0